// App-Quantinova.ai

: Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy

Researchers

Presenter

  • Johannes M. Waldschmidt

Principal Investigators

  • Sankalp Arora

  • Tushara Vijaykumar

  • Noori Sotudeh

  • Praveen Anand

  • Hannah Stuart

  • Julia Frede

  • Tim Campbell

  • Shari M. Kaiser

  • Manisha Lamba

  • Nikhil C Munshi

  • Kenneth C. Anderson

  • Andrew J. Yee

  • Birgit Knoechel

  • Jens G. Lohr

  • Noopur Raje

Medical Centers

  • Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

  • University of Alabama at Birmingham, Birmingham, AL

  • Massachusetts General Hospital, Boston, MA

  • Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA

  • Department of Hematology, Oncology and Stem Cell Transplantation, University of Freiburg Medical Center, Freiburg, Germany

  • Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • Cluster of Differentiation 2AP

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved